Faeth Therapeutics Appoints Dr. Stephen Hahn and Dr. Jayson Dallas to Board of Directors

BusinesswireNov 22 20:00

FDA Approves U.S. Pediatric Indication Extension for Palforzia Oral Immunotherapy for the Treatment of Peanut Allergy

BusinesswireJul 30 18:09

Aimmune Therapeutics to Present Positive Results From Phase 3 POSEIDON Study of PALFORZIA® [Peanut (Arachis Hypogaea) Allergen Powder-dnfp] in Peanut-Allergic Children Aged 1 to 3 Years

BusinesswireNov 10, 2022 21:06

Allergy Partners Announces Collaboration With Aimmune Therapeutics to Provide PALFORZIA® [Peanut (Arachis Hypogaea) Allergen Powder-dnfp] Directly to Patients

BusinesswireOct 14, 2022 05:20

Global Food Allergy Market Report to 2032 - Featuring Aimmune Therapeutics, Novartis Pharmaceuticals and DBV Technologies Among Others - ResearchAndMarkets.com

BusinesswireJul 6, 2022 22:51

Aimmune Therapeutics to Present New Data for PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] at the EAACI Hybrid Congress 2022

BusinessWireJul 1, 2022 06:06